Novartis said the results of two Phase-3 studies of ACZ885 (canakinumab) indicate that the human monoclonal antibody can slow attacks of severe gouty arthritis by up to 68% when compared with the standard steroid treatment (triamcinolone acetonide TA).
Privately-owned GenKyoTex SA has raised 14.5 million Euro to bring a compound for diabetic nephropathy into the clinic and advance other programmes. The Series C round was led by Edmond de Rothschild Investment Partners of Paris, France.
Lab21 Ltd, a diagnostic service provider, has announced the acquisition of Myconostica Ltd of the UK which develops molecular tests for the diagnosis of fungal infections. Financial terms weren’t disclosed.
Evotec AG and the Roche group said they have voluntarily ended a Phase 2 proof-of-concept study in a candidate molecule for treatment-resistant depression. The decision was triggered by difficulties recruiting patients under the study protocol.
Takeda Pharmaceutical Company Ltd is set to significantly increase its commercial presence in Europe with the planned acquisition of privately-owned Nycomed A/S of Switzerland. Under the agreed takeover, Takeda will pay €9.6 billion in cash to Nycomed’s shareholders who are members of a consortium of private equity funds led by Nordic Capital Private Equity Funds.
Curetis AG, a molecular diagnostics company specialising in the development of in-vitro diagnostic products for infectious diseases, has raised €4.5 million in an extension of a Series A financing, bringing the total for the round to €24.5 million.
A French company that specialises in biomarkers for cancer, Median Technologies, has raised €10 million in a private placement of its shares with institutional investors. The company is also planning an initial public offering on NYSE Euronext Paris.
Shire Plc has announced an agreement to acquire the privately-held US regenerative medicines company, Advanced BioHealing Inc, for $750 million in cash. The US company has a marketed product for diabetic foot ulcers.
The Roche group and Merck & Co have announced a number of non-exclusive agreements under which they will explore new combinations of investigational and marketed medicines for hepatitis C. This follows FDA approval of the Merck HCV drug, Victrelis.
ArGEN-X NV, a young Dutch antibody company whose technology is based on the llama, has progressed a candidate antibody into preclinical development, its second therapeutic candidate. The compound targets an undisclosed cancer cell receptor.